Meiji Seika Pharma Co Ltd said its subsidiary, Meiji Pharma Asia Pte Ltd, began operations in Singapore on April 1, marking a strategic step to expand its presence in ASEAN.
The company said the new unit will handle the commercialisation, marketing and distribution of pharmaceuticals, including vaccines, across the region.
Singapore will serve as a regional hub to drive business strategy and accelerate growth in ASEAN markets.
Established on Dec 10, 2025, Meiji Pharma Asia will focus on treatments for infectious diseases, haematologic cancers and lifestyle-related conditions, while supporting reliable supply and contributing to public health.
The move aligns with Meiji Seika Pharma’s “Meiji Group 2026 Vision” to become a leading player in Asia’s infectious diseases segment, building on decades of experience in Thailand and Indonesia.
